Entries by Tanya Samazan

Biden Administration Backs Science

Early signs from the Biden Administration indicate the Administration is elevating the role of science in its policymaking and actions. President Biden has already promoted the role of science advisor and director of the Office of Science and Technology policy to the level of a Cabinet position. Made up of 25 members, Cabinet members serve […]

SARS-CoV-2 Vaccines: Phase 1 vs. Phase 3

With US regulatory emergency use authorization (EUA) of two vaccines, a major threshold has been crossed in the response to COVID-19. According to the latest information, dated December 16, from the World Health Organization (WHO), more SARS-CoV-2 vaccine candidates are moving closer to completing the clinical trial phase. Twenty percent of the candidates in clinical […]

COVID-19 Pandemic Rattles European Universities’ Finances

This month, the European University Association, a representative of more than 800 European universities, issued a new report, “Public Funding Observatory 2020/2021: Part 1: Financial and economic impact of the COVID-19 crisis on universities in Europe.” The report is based on a survey conducted this summer of 29 national European university associations. The report illustrates […]

Life Science Tool Companies’ IPOs Show Impressive Gains

As the stock market continues its gyrations this year in the face of the unprecedented circumstances of COVID-19 and subsequent macroeconomic downtown, how are life science tool companies’ stocks doing? One way to answer this question is to look at companies that have completed IPOs over the past two years. New to the public market […]

US Business R&D Tops $440 Billion in 2018

Published this month, the National Science Foundation’s (NSF’s) review of US business R&D spending in 2018 indicates the robust contribution of business R&D to the economy and the diversity of industries conducting R&D in the US. It also lays out the importance of both manufacturing and non-manufacturing R&D to innovation. Top Spending Total US businesses’ […]

Sequencing Resources Must Progress to Fight COVID-19

A new consensus report, “Genomic Epidemiology Data Infrastructure Needs for SARS-CoV-2: Modernizing Pandemic Response Strategies,” from the National Academy of Sciences offers recommendations to address the SARS-CoV-2 pandemic through the integration of genomic, clinical and epidemiological data. The main focus of the report is how viral sequencing is being utilized to address COVID-19 and the […]

Pall Debuts Filtration Solutions for Biotech Research

As the number of biotech drugs in development grows exponentially, lab protein and cell purification workflows are facing increasing demand. Such workflows include clone selection, cell expansion studies and recombinant protein isolation prior to analysis. Suppliers of filtration and clarification consumables have responded by innovating to accelerate these workflows. Pall, one of the largest suppliers […]

NIH Lays Out Vision for Nutrition Research

The National Instituts of Health (NIH) has released the “2020–2030 Strategic Plan for NIH Nutrition Research,” developed by the NIH Nutritional Research Task Force. The report calls for research investments in Precision Nutrition. Unlike personalized nutrition or nutrigenomcis, Precision Nutrituion encompasses both internal and external contributions: diet, genetics, physical health, microbiome, metabolism, dietary habits, activity […]

A Continuous Flow of Investments in COVID-19 R&D

In the IBO blog’s fourth look at coronavirus-related R&D funding, the focus is on announcements made in May. Governments continue to make large commitments, with funding ultimately designated for universities, research institutes, the private sector, and infectious disease research organizations that will coordinate efforts to funnel money to all three sectors. These organizations include CEPI […]

A Steady Stream of New Funding for COVID-19 R&D

This is the third of IBO’s review of R&D investments related to COVID-19 (see March 27 and April 17). The outbreak has triggered a wide range of responses spanning immediate and long-term solutions. For R&D, spending priorities range from areas  such as new diagnostic approaches and vaccine development to basic research in fields such as […]